Security
Tarsus Pharmaceuticals, Inc. Common Stock · TARS
TARSNASDAQCommon stockCurrentCIK 1819790Updated Oct 14, 2026
TARS price & chart
Loading TradingView…
NASDAQ:TARS on TradingView ↗About the company
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution, 0.25%) is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease.
In the news
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
S-3ASR filing
S-3ASR filing
Financial Statements and Exhibits
Items 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 534,561,000Source | 376,300,000Source | 611,142,000Source | 494,994,000Source | 376,844,000Source | 581,135,000Source | 500,750,000Source | 349,278,000Source | 562,158,000Source | 376,991,000Source | 265,491,000Source | 227,863,000Source |
| Property, Plant and Equipment, NetUSD | 5,746,000Source | 2,393,000Source | 20,489,000Source | 3,182,000Source | 2,241,000Source | 17,672,000Source | 2,787,000Source | 1,338,000Source | 11,665,000Source | 2,314,000Source | 1,468,000Source | 957,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 7,606,000Source | 8,567,000Source | 6,885,000Source | 7,846,000Source | 3,667,000Source | 7,126,000Source | 8,086,000Source | 3,767,000Source | 7,366,000Source | 8,326,000Source | 3,867,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 112,724,000Source | 176,210,000Source | 204,595,000Source | 96,648,000Source | 181,095,000Source | 102,192,000Source | 175,787,000Source | 193,706,000Source | 183,640,000Source | 94,818,000Source | 224,947,000Source | 71,660,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 72,620,000Source | 29,159,000Source | 96,028,000Source | 58,334,000Source | 29,529,000Source | 100,344,000Source | 62,426,000Source | 29,885,000Source | 85,057,000Source | 46,760,000Source | 16,621,000Source | — |
| Inventory, NetUSD | 3,836,000Source | 2,846,000Source | 4,377,000Source | 3,873,000Source | 2,195,000Source | 4,572,000Source | 2,705,000Source | 4,036,000Source | 4,372,000Source | 2,620,000Source | 3,107,000Source | — |
| Assets, CurrentUSD | 501,704,000Source | 357,117,000Source | 561,989,000Source | 474,429,000Source | 362,588,000Source | 537,229,000Source | 480,773,000Source | 340,724,000Source | 522,782,000Source | 356,705,000Source | 256,131,000Source | 225,375,000Source |
| Operating Lease, Right-of-Use AssetUSD | 10,233,000Source | 1,802,000Source | 9,911,000Source | 229,000Source | 1,969,000Source | 9,994,000Source | 393,000Source | 2,132,000Source | 10,080,000Source | 552,000Source | 1,880,000Source | 575,000Source |
| Other Assets, NoncurrentUSD | 1,177,000Source | 888,000Source | 660,000Source | 1,213,000Source | 846,000Source | 715,000Source | 616,000Source | 1,317,000Source | 1,861,000Source | 999,000Source | 1,514,000Source | 585,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 199,479,000Source | 138,816,000Source | 264,410,000Source | 162,382,000Source | 124,598,000Source | 232,184,000Source | 158,292,000Source | 74,067,000Source | 218,732,000Source | 152,457,000Source | 68,503,000Source | 34,963,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 5,000Source | 5,000Source |
| Additional Paid in CapitalUSD | 753,042,000Source | 574,229,000Source | 799,429,000Source | 738,237,000Source | 566,093,000Source | 782,838,000Source | 727,697,000Source | 555,655,000Source | 769,667,000Source | 584,559,000Source | 441,641,000Source | 301,732,000Source |
| Retained Earnings (Accumulated Deficit)USD | -418,255,000Source | -337,097,000Source | -452,146,000Source | -405,670,000Source | -313,677,000Source | -433,595,000Source | -385,330,000Source | -280,387,000Source | -426,628,000Source | -360,210,000Source | -244,656,000Source | -108,763,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 289,000Source | 346,000Source | -557,000Source | 39,000Source | -176,000Source | -298,000Source | 85,000Source | -63,000Source | 381,000Source | 179,000Source | -2,000Source | -74,000Source |
| Stockholders' Equity Attributable to ParentUSD | 335,082,000Source | 237,484,000Source | 346,732,000Source | 332,612,000Source | 252,246,000Source | 348,951,000Source | 342,458,000Source | 275,211,000Source | 343,426,000Source | 224,534,000Source | 196,988,000Source | 192,900,000Source |
| Liabilities and EquityUSD | 534,561,000Source | 376,300,000Source | 611,142,000Source | 494,994,000Source | 376,844,000Source | 581,135,000Source | 500,750,000Source | 349,278,000Source | 562,158,000Source | 376,991,000Source | 265,491,000Source | 227,863,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 117,050,000Source | 65,868,000Source | 175,753,000Source | 90,253,000Source | 51,571,000Source | 143,508,000Source | 86,308,000Source | 42,528,000Source | 135,695,000Source | 80,612,000Source | 36,936,000Source | 15,429,000Source |
| Operating Lease, Liability, CurrentUSD | 80,000Source | 631,000Source | 154,000Source | 317,000Source | 605,000Source | 0Source | 384,000Source | 585,000Source | 0Source | 608,000Source | 398,000Source | 721,000Source |
| Accounts Payable, CurrentUSD | — | — | 40,141,000Source | — | — | 24,131,000Source | — | — | 16,387,000Source | — | — | — |
| Operating Lease, Liability, NoncurrentUSD | 10,148,000Source | 1,241,000Source | 15,895,000Source | 0Source | 1,449,000Source | 16,079,000Source | 0Source | 1,606,000Source | 10,599,000Source | 0Source | 1,515,000Source | 52,000Source |
| Other Liabilities, NoncurrentUSD | 10,148,000Source | 1,240,000Source | 15,895,000Source | — | 1,449,000Source | 16,079,000Source | — | 1,606,000Source | 10,599,000Source | 0Source | 1,748,000Source | 100,000Source |
| Additional Financial Items | ||||||||||||
| Long-term Debt, Excluding Current MaturitiesUSD | 72,281,000Source | 71,708,000Source | 72,762,000Source | 72,129,000Source | 71,578,000Source | 72,597,000Source | 71,984,000Source | 29,933,000Source | 72,438,000Source | 71,845,000Source | 29,819,000Source | 19,434,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 72,281,000Source | 71,708,000Source | 72,762,000Source | 72,129,000Source | 71,578,000Source | 72,597,000Source | 71,984,000Source | 29,933,000Source | 72,438,000Source | 71,845,000Source | 29,819,000Source | 19,434,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | — | — | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 11,967,000Source | 6,930,000Source | 41,720,000Source | 27,818,000Source | 19,830,000Source | 13,460,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 30,287,000Source | 15,666,000Source | 38,297,000Source | 30,139,000Source | 16,621,000Source | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 196,000Source | 84,000Source | 1,751,000Source | 2,046,000Source | 3,107,000Source | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -24,652,000Source | -20,651,000Source | -12,451,000Source | -83,027,000Source | -117,493,000Source | -49,030,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -58,562,000Source | -34,942,000Source | -42,115,000Source | -199,195,000Source | 140,604,000Source | -144,629,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 5,818,000Source | 590,000Source | 9,859,000Source | 1,567,000Source | 1,502,000Source | 506,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 1,204,000Source | 136,562,000Source | 143,388,000Source | 154,656,000Source | 130,176,000Source | 93,987,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -82,010,000Source | 80,969,000Source | 88,822,000Source | -127,566,000Source | 153,287,000Source | -99,672,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 115,287,000Source | 176,210,000Source | 206,596,000Source | 99,211,000Source | 104,193,000Source | 178,350,000Source | 186,203,000Source | 97,381,000Source | 224,947,000Source | 71,660,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,969,000Source | 2,074,000Source | 8,342,000Source | 7,662,000Source | 2,880,000Source | 1,675,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 12,243,000Source | 7,415,000Source | 13,289,000Source | 8,234,000Source | 11,967,000Source | 6,930,000Source | 41,720,000Source | 27,818,000Source | 19,830,000Source | 13,460,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | 152,000Source | 129,000Source | 165,000Source | 146,000Source | 159,000Source | 139,000Source | 593,000Source | 402,000Source | 121,000Source | 135,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 159,000Source | 139,000Source | 593,000Source | 482,000Source | 385,000Source | 309,000Source |
| Amortization of Intangible AssetsUSD | — | — | 200,000Source | 100,000Source | 200,000Source | 200,000Source | 240,000Source | 240,000Source | 961,000Source | 540,000Source | 133,000Source | — |
| DepreciationUSD | — | — | 200,000Source | 200,000Source | 800,000Source | 200,000Source | 197,000Source | 220,000Source | 855,000Source | 685,000Source | 744,000Source | 300,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | — | 0Source | — | — | — | 0Source | 0Source | -591,000Source | — | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | 259,000Source | -268,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -1,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 0Source | 0Source | — | 0Source | — | — | 0Source | -1,944,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | — | 57,910,000Source | — | — | — | — | — | — | — | 44,949,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | 2,716,000Source | 0Source | 2,352,000Source | 0Source | 2,059,000Source | 0Source | 0Source | -4,000Source |
| InterestExpenseNonoperatingUSD | — | — | 2,268,000Source | 2,445,000Source | 2,156,000Source | 2,240,000Source | 2,128,000Source | 2,213,000Source | 8,935,000Source | 7,849,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -12,585,000Source | -23,420,000Source | -18,551,000Source | -20,340,000Source | -6,967,000Source | -25,120,000Source | -66,418,000Source | -115,554,000Source | -135,893,000Source | -62,091,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,944,000Source | 1,742,000Source | 4,073,000Source | 1,844,000Source | 1,507,000Source | 1,160,000Source | 6,610,000Source | 5,015,000Source | 7,265,000Source | 617,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 160,605,000Source | 88,528,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 2,500,000Source | — | — | — |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Other Nonoperating Income (Expense)USD | — | — | 98,000Source | 67,000Source | -281,000Source | -145,000Source | -87,000Source | -81,000Source | -202,000Source | 586,000Source | -102,000Source | 86,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | 0Source | 75,000,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,204,000Source | 1,437,000Source | 6,280,000Source | 5,609,000Source | 592,000Source | 123,000Source |
| Income Taxes Paid, Net | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | — | — | — | — | — | — | — | — | — | — |
| Gain (Loss) on Investments | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 118,697,000Source | 48,118,000Source | 173,912,000Source | 102,660,000Source | 162,054,000Source | 78,335,000Source | 451,360,000Source | 182,953,000Source | 17,447,000Source | 25,816,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 108,633,000Source | 57,910,000Source | 150,697,000Source | 103,013,000Source | 136,429,000Source | 84,995,000Source | 427,323,000Source | 237,310,000Source | 108,700,000Source | — |
| Operating Income (Loss)USD | — | — | -14,529,000Source | -25,162,000Source | -19,908,000Source | -22,184,000Source | -6,122,000Source | -26,280,000Source | -70,969,000Source | -120,569,000Source | -143,158,000Source | -62,712,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 98,000Source | 67,000Source | -281,000Source | -145,000Source | -87,000Source | -81,000Source | -202,000Source | 586,000Source | -102,000Source | 86,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -64,359,000Source | -115,554,000Source | -135,893,000Source | -62,095,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 2,716,000Source | 0Source | 2,352,000Source | 0Source | 2,059,000Source | 0Source | 0Source | -4,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -12,585,000Source | -23,420,000Source | -18,551,000Source | -20,340,000Source | -6,967,000Source | -25,120,000Source | -66,418,000Source | -115,554,000Source | -135,893,000Source | -62,091,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.3Source | -0.61Source | -0.43Source | -0.48Source | -0.16Source | -0.64Source | -1.59Source | -3.07Source | -4.62Source | -2.52Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.3Source | -0.61Source | -0.43Source | -0.48Source | -0.16Source | -0.64Source | -1.59Source | -3.07Source | -4.62Source | -2.52Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 42,607,717Source | 38,381,968Source | 43,393,643Source | 42,360,452Source | 42,956,973Source | 39,345,359Source | 41,784,014Source | 37,604,538Source | 29,383,276Source | 24,619,700Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 42,607,717Source | 38,381,968Source | 43,393,643Source | 42,360,452Source | 42,956,973Source | 39,345,359Source | 41,784,014Source | 37,604,538Source | 29,383,276Source | 24,619,700Source |
| Interest Expense (non-operating)USD | — | — | 2,268,000Source | 2,445,000Source | 2,156,000Source | 2,240,000Source | 2,128,000Source | 2,213,000Source | 8,935,000Source | 7,849,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 200,000Source | 100,000Source | 200,000Source | 200,000Source | 240,000Source | 240,000Source | 961,000Source | 540,000Source | 133,000Source | — |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Costs and ExpensesUSD | — | — | 133,226,000Source | 73,280,000Source | 193,820,000Source | 124,844,000Source | 168,176,000Source | 104,615,000Source | 522,329,000Source | 303,522,000Source | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 2,059,000Source | 0Source | 0Source | -4,000Source |
| General and Administrative ExpenseUSD | — | — | — | 57,910,000Source | — | — | — | — | — | — | — | 44,949,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -64,359,000Source | -115,554,000Source | -135,893,000Source | -62,095,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 3,346,000Source | 2,199,000Source |
| Interest Expense, DebtUSD | — | — | 2,268,000Source | 2,445,000Source | 2,156,000Source | 2,240,000Source | 2,128,000Source | 2,213,000Source | 8,935,000Source | 7,849,000Source | 3,346,000Source | 2,199,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | — | — | — | — | — | — | — | 10,337,000Source | 3,499,000Source |
| Interest Income, OtherUSD | — | — | 4,114,000Source | 4,120,000Source | 3,698,000Source | 4,229,000Source | 3,722,000Source | 3,454,000Source | 15,747,000Source | 15,014,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 1,944,000Source | 1,742,000Source | 4,073,000Source | 1,844,000Source | 1,507,000Source | 1,160,000Source | 6,610,000Source | 5,015,000Source | 7,265,000Source | 617,000Source |
| Operating ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 160,605,000Source | 88,528,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | 2,500,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 16,284,000Source | 12,128,000Source | 31,010,000Source | 15,594,000Source | 22,351,000Source | 14,409,000Source | 64,322,000Source | 53,386,000Source | 50,312,000Source | 42,624,000Source |
| Cost of Revenue | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | — | — | — | — | — | — | — | — | — | — |
| Gain (Loss) on Investments | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-299429
Registration 333-299435
Filing attachments
d901047dex991.htm · 8-K · 2025-03-13
EX-99.1 4 d901047dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tarsus Announces Proposed $100.0 Million Public Offering IRVINE, Calif., March 12, 2025 (GLOBAL NEWSWIRE) - Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock. Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock o…
Read attachment ↗d901047dex992.htm · 8-K · 2025-03-13
EX-99.2 5 d901047dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Tarsus Announces Pricing of Upsized $125.0 Million Public Offering IRVINE, Calif., March 12, 2025 - Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public offering price of $44.50 per share. In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 421,348 …
Read attachment ↗d892013dex991.htm · 8-K · 2025-01-13
EX-99.1 2 d892013dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 The Future of Eye Care Begins Here January 2025 ® Matt, an XDEMVY Patient Forward-Looking Statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These include statements regarding the potential commercial success and growth of XDEMVY in Demodex blepharitis, including market …
Read attachment ↗